Goldman Sachs initiated coverage on Insmed Inc. with a Buy rating and a $188.00 price target. This valuation represents significant potential upside from the current trading price.
Analysts identified the biopharmaceutical company as an attractive opportunity due to its undervalued development pipeline and lower commercial risk. The bank also highlighted the broader biotechnology sector's resilience as a driver for the coverage.
Insmed focuses on developing treatments for serious and rare diseases. Its lead product, Arikayce, is currently approved for a specific type of lung disease. The company continues to report positive revenue trends as it advances its clinical pipeline.